Seelos Therapeutics
@seelostxSeelos Therapeutics, Inc. (Nasdaq: SEEL), is a clinical-stage biopharmaceutical company $SEEL
Similar User
@psyinvest
@alsassociation
@Optimi_Health
@Pharmather_Inc
@SageBiotech
@mirumpharma
@Geovax_News
@GMGI_Official
@AfcAish
@alpine4holdings
@Revive_RVV
@Cytokinetics
@NeurosenseT
@OzopEnergy
@PSYCCorp
"With ketamine’s effects being both fast-acting and long-lasting, a single dose of ketamine could have a more durable effect than SSRIs taken daily" drugdiscoverynews.com/uncovering-the… @DrugDiscovNews #ptsd #MentalHealth #ketamine
This May, for Mental Health Awareness Month, we are continuing to #TalkAwayTheDark! This campaign has educated people across the country on how to spot the warning signs for suicide and begin a conversation that lets someone who needs support know that help is available.
Seelos Announces Strategic Focus on Mental Health Initiatives and Provides Update on Current Discussions of Potential Partnerships and Collaborations; Richard Pascoe appointed Chairman of the Board to spearhead the ongoing business development discussions seelostherapeutics.com/press-releases…
Seelos' SLS-005 Top-Line ALS results show a 22% improvement in slope of change in ALSFRS-R adjusted for mortality, decline/mo. favoring SLS-005, plus a 25% slowing of SVC decline versus placebo at 24 weeks -Seelos plans to request a meeting with FDA seelostherapeutics.com/press-releases…
TDP-43 pathology is a defining feature in almost all patients with ALS and about half of those with FTD. nih.gov/news-events/ne…
This landmark paper opens the door to next gen of treatments, changing the definition based on biological framework for PD rather than just its symptoms, neuronal α-synuclein disease. SLS-004 works by reducing α-synuclein. @CPathInstitute @MichaelJFoxOrg michaeljfox.org/news/first-bio…
Seelos announces minutes from its EOP II Meeting, will continue potential partner discussions, Phase III plan is for 1 study using MADRS Day 16 as Primary Endpt and Suicide at 24 hours as key Secondary Endpt, Design aligns with stat sig data from Phase II seelostherapeutics.com/press-releases…
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote “FOR” All Proxy Proposals at the Special Meeting to be held on January 10, 2024 seelostherapeutics.com/press-releases…
Seelos Therapeutics, Inc. Releases Letter to its Stockholders CEO Raj Mehra provide updates on lead programs, an update on potential partnering and collaboration process as well as the upcoming special meeting of stockholders. seelostherapeutics.com/press-releases…
The Seelos R&D team is looking forward to our face-to-face, End of Phase 2 meeting for SLS-002 (intranasal racemic ketamine) with FDA next week on Wed Dec. 20th seelostherapeutics.com/sls-002-ketami… #SuicidePrevention #ketamine
Number of suicides in the US in 2022 reaches record level. An estimated 49,449 people died by suicide, which is 3% higher than 2021. abcnews.go.com/Health/number-… #SuicidePrevention #ketamine
Seelos Announces the Selection of SLS-002 for Inclusion in U.S. Department of Defense’s Adaptive Platform Trial Evaluating Potential Treatments for PTSD and is funded by The U.S. Department of Defense’s Defense Health Agency seelostherapeutics.com/press-releases… #PTSD #ketamine @DeptofDefense
Good luck this morning Krishna ! @SfNtweets #Alzheimers #Autophagy
Seelos to Present a Poster on SLS-005 in Alzheimer’s at Neuroscience 2023 @SfNtweets -SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's, Huntington's, ALS and Spinocerebellar ataxia seelostherapeutics.com/press-releases…
Seelos to Present a Poster on SLS-005 in Alzheimer’s at Neuroscience 2023 @SfNtweets -SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's, Huntington's, ALS and Spinocerebellar ataxia seelostherapeutics.com/press-releases…
Yesterday in Boston, Krishna Subramanian, PhD participated in a panel titled "Novel Nasal Products and Formulations" at the 13th Annual Partnership Opportunities in Drug Delivery #PODD2023 to discuss our SLS-002 moderated by Samantha Sarett of Eli Lilly.
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations seelostherapeutics.com/press-releases…
While 78% think mental health is as important as physical health, only 34% globally say their country’s healthcare system treats them equally. ipsos.com/en/world-menta… #WorldMentalHealthDay
biospace.com/article/four-h… BioSpace spoke with Graig Suvannavejh, managing director of equity research at Mizuho to discuss upcoming data including our SLS-005 in ALS on the @MGHNeurology Healey Platform trial. #ENDALS #HealeyHope
US health care workers face elevated risk of suicide, new study finds cnn.com/2023/09/26/hea… #SuicidePreventionMonth
Seelos Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease; demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from within 6 mos #alzheimers #EndALS seelostherapeutics.com/press-releases…
United States Trends
- 1. Cowboys 66 B posts
- 2. Texans 55,6 B posts
- 3. Cooper Rush 11,5 B posts
- 4. Jerry 42 B posts
- 5. Mike McCarthy 3.007 posts
- 6. Trey Lance 3.033 posts
- 7. Joe Mixon 9.860 posts
- 8. #WWERaw 60,4 B posts
- 9. Dyson Daniels 2.205 posts
- 10. Keon Ellis 1.442 posts
- 11. #HOUvsDAL 9.217 posts
- 12. Norman Powell N/A
- 13. Sixers 10,7 B posts
- 14. Pulisic 22,8 B posts
- 15. The Herta 16,8 B posts
- 16. Aubrey 15,6 B posts
- 17. Derek Barnett 1.779 posts
- 18. #HTownMade 3.637 posts
- 19. Zack Martin N/A
- 20. Guyton 1.408 posts
Who to follow
-
Psychedelic Invest
@psyinvest -
The ALS Association
@alsassociation -
Optimi
@Optimi_Health -
PharmaTher Holdings Ltd.
@Pharmather_Inc -
Sage Therapeutics
@SageBiotech -
Mirum Pharmaceuticals
@mirumpharma -
GeoVax, Inc.
@Geovax_News -
Golden Matrix Group
@GMGI_Official -
A
@AfcAish -
Alpine 4 Holdings, Inc.
@alpine4holdings -
Revive Therapeutics (CSE: RVV, US: RVVTF) Official
@Revive_RVV -
Cytokinetics
@Cytokinetics -
NeuroSense Therapeutics
@NeurosenseT -
OZOP Energy Solutions
@OzopEnergy -
PSYC Corp.
@PSYCCorp
Something went wrong.
Something went wrong.